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Available online 26 December 2019One speciﬁc technological advance in transdermal drug delivery is the development of dissolving microneedles
(DMNs), which efﬁciently deliver therapeutics through a rapid dissolution of polymers after penetration into
the skin. However, there is a limited range of water soluble, biodegradable polymers that can be used to manu-
facture DMN. Here, we report for the ﬁrst time, the preparation and characterisation of a DMN system from the
carbohydrate biopolymer, pullulan (PL). PL gels, of varying concentration, were studied for viscosity, ﬁlm forma-
tion properties, and subsequently, microneedle formation. Model molecules and protein/peptide were loaded
into PL DMN and characterised. The stability of model biomolecules, such as FITC-BSA and insulin, following
DMN manufacture were assessed using circular dichroism. Ex-vivo porcine skin permeation studies using
Franz diffusion cell apparatus for Flu-Na and FITC-BSA loaded PL-DMNwere conducted. This study demonstrates
that PL DMNs may serve as a promising tool for efﬁcient transdermal drug delivery.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Transdermal drug delivery systems (TDDS) are well-known within
the pharmaceutical domain since the invention of nitroglycerin oint-
ment [1]. Transdermal administration is a favoured route of administra-
tion as it provides advantages such as improved dosage efﬁcacy with
controlled or prolonged drug delivery, enhanced patient compliance,
and reduced systemic side effects [2]. Importantly, however, the outer-
most barrier of the skin, the stratum corneum (SC), allows only low-
molecular-mass lipophilic drugs to passively penetrate the skin. This
SC barrier considerably limits the transdermal delivery of larger mole-
cules such as proteins and therapeutic genes. To increase the permeabil-
ity of the SC, techniques such as ultrasound, iontophoresis,
electroporation, thermal ablation and microdermabrasion have been
developed. However, most of these techniques have not progressed
past the pre-clinical phase of testing due to the risk of skin irritation,
which is unacceptable in a clinical setting [3]. Permeation enhancer
and prodrug approaches have also been explored extensively for TDDS
with limited success [4].
To overcome the challenges associated with current technologies,
microneedle (MN) arrays are currently of signiﬁcant interest in both
transdermal drug delivery and transdermal diagnostics. MNs are mini-
mally invasive devices consisting of numerousmicron-sized projections. This is an open access article underarranged on a baseplate. The MNs perforate the SC, forming temporary
aqueous micropores throughwhich drugs can diffuse to the dermal mi-
crocirculation. However, with an average height of 400–900 μm, MNs
are short enough to avoid stimulation of dermal nerves and do not in-
duce bleeding [5,6].
First-generation MNs, made from silicon, metals or glass, were de-
signed to create the pore in the skin into which the drug or vaccine dif-
fused. The disadvantages of these types ofMNs are; limited loading dose
of drugs, and the critical risk that MNs can be accidentally broken and
therefore remain in the skin for a long period of time. Consequently,
microneedle arrays which are fabricated from biodegradable [7] or dis-
solvingpolymers, have recently received considerable attention [8]. Dis-
solving MN (DMN) arrays are fabricated to incorporate drug molecules
into a soluble polymericmatrix and the drugs can be released in the skin
upon dissolving the inserted MNs. The advantage of this new kind of
DMNs is that they can be formulated more cost-effectively compared
to silicon or metal MNs. Neither do they pose a safety concern as the
sharp tips fully dissolve in skin interstitial ﬂuid to release their drug pay-
load. Unlike coated metal or silicon MNs, drugs can be encapsulated
within the matrix of polymeric MNs, dramatically increasing their
drug loading capacity [9]. Usingdifferent polymers that display different
degradation proﬁles, swelling properties and responses to biological/
physical stimuli can allow for the development of customisable drug de-
livery systems. Moreover, the use of DMN can effectively extend the
shelf-life of proteins/peptides, and lower the cost of cold chain pro-
cesses compared to their conventional solution-based counterparts
[10].the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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can be used to manufacture MNs. Addition to that, water-soluble poly-
mers generally have weaker mechanical strength compared to non-
dissolving materials like silicon or metal, and drug encapsulation may
further weaken their biomechanical strength [11,12]. Thus, appropriate
geometry design and material selection are particularly important for
dissolvable MNs fabrication. To date, dissolving MNs have been fabri-
cated from various materials, such as sugars, galactose [12], carboxy-
methylcellulose [13], poly(vinylpyrrolidone) [14,35], poly (methyl
vinyl ether-maleic acid) [15], chondroitin sulfate [16] sodium
hyaluronate (HA) [17] and Poly(vinyl alcohol) [31]. Nevertheless, we
reported the serious processing, handling and mechanical stability is-
sueswith carbohydrate and sugar-basedMNs [12]. Considering the lim-
itations of explored polymeric materials for MN drug delivery, the ﬁlm-
forming carbohydrate biopolymer, pullulanwas investigated in this cur-
rent work to fabricate the self-dissolving MN for the delivery of model
small and large biomolecules.
Pullulan (PL) is a natural polymer produced by the yeast like fungus
Aureobasidium pullulans in starch and sugar cultures. PL is a hydrophilic
linear biopolymermainly consisting ofmaltotriose units interconnected
α-(1,6) glycoside bonds. This unique linkage pattern provides pullulan
with exceptional physical properties to form ﬁlm that is mechanically
strong, transparent, water-soluble and with low permeability to oil
and oxygen [18]. Addition to that, there is no toxicity or mutagenicity
[19]. PL is easy to chemicallymodify because it hasmore numbers of hy-
droxyl groups. Owing to these peculiar characteristics, PL and PL deriv-
atives hold a vital role in numerous biomedical applications such as
tissue engineering, oral ﬁlms, capsule coating, vaccination, targeted
drug and gene delivery [18,20]. Therefore, high hydrophilicity, good
mechanical strength and biocompatibility make PL an excellent candi-
date to manufacture the dissolving MN. This is the ﬁrst study to prove
the use of carbohydrate polymer PL, for dissolving MNs patches for
transdermal delivery.
The aim of this study was to develop DMN from the carbohydrate
biopolymer PL for transdermal delivery of small molecule drugs and
biomolecules. The ﬁrst objective was to investigate the rheological and
mechanical properties of PL to assess the required formulation charac-
teristics for DMN fabrication. The mechanical strength of drug-free
DMN was evaluated, and the insertion capability in neonatal porcine
skin was investigated. Following this, PL DMN formulationswere devel-
oped and characterised with model small molecules (methylene blue
and ﬂuorescein sodium) and with large protein/peptide biomolecules
(FITC-BSA and insulin).
2. Materials and methods
2.1. Materials
Phosphate buffered saline (PBS), ﬂuorescein sodium, methylene
blue, ﬂuorescein isothiocyanate labelled bovine serum albumin (FITC-
BSA), insulin (human recombinant, produced by recombinant DNA
technology in yeast Saccharomyces cerevisiae, N27.5 IU/mg) were pur-
chased fromSigmaAldrich Co. (St. Louis,MO, USA). Double distilled ion-
ized water was prepared using NanoPure Inﬁnity Ultrapure water
puriﬁcation system. Pullulan (viscosity: 133 mm2/s, 10%w/w,
Ubbelohde type viscometer, averageMw 200 kDa) was kindly provided
by Hayashibara Ltd. (Japan). Paraﬁlm®M (~127 μm thickness), made of
oleﬁn-type materials, was purchased from Brand GMBH (Wertheim,
Germany). All other chemicals used were of analytical reagent grade.
2.2. Rheological study of PL gel
Rheological characterisation of different concentrations of PL gelwas
performedusing a TA instruments AR 1500Rheometer (TA instruments,
Elstree, Herts, UK) ﬁtted with a 40 mm diameter steel parallel plate.
Flow rheology testing was conducted at continuous controlled rampmode with the shear rate increased from 0 to 50/s and 25 °C. Viscosity
was determined by the application of the Power law.
2.3. Preparation and characterisation of PL ﬁlm
PL ﬁlms were prepared by casting the different concentrations of
aqueous gels of PL (10%, 15% 20% and 25% w/w). Each solution was
added to an individual mould consisting of a stainless steel frame se-
cured on 5 cm × 2 cm Perspex® base. To allowing even spreading of
the solution, the mould was placed on a ﬂat surface and dried at room
temperature for 48 h. Film thickness was measured by using a digital
micrometer (Hilka, ProCraft, Surrey, UK). A TA-XT2 Texture Analyser
(Stable Microsystems, Haslemere, UK) was used to conduct tensile
strength using PL ﬁlm strips (50 mm× 5 mm). The strips were secured
between two grips set at 20 mm spacing and a cross-head speed of
0.5 mm/s was used.
2.4. Fabrication of plain PL DMN
PL DMN arrays were fabricated from aqueous solutions of PL (10%,
15% 20% and 25% w/w) as summarized in Fig. 1. Approximately
500 mg of blend was poured into laser-engineered silicone conical
19 × 19 (19 × 19 needle array density per 0.49 cm2 area, 600 μmneedle
height, 300 μm needle width at the base, and 150 μm interspacing) and
12 × 12 arrays (12 × 12 needle array density per 0.49 cm2 area, 600 μm
needle height, 300 μm needle width at the base, and 150 μm
interspacing) micromould templates. The ﬁlled moulds were centri-
fuged at 2205 ×g for 15min. Finally, the arrays were dried at room tem-
perature for 48 h and they were stored at room temperature in a
desiccator prior to the analysis. Drying time and temperature parame-
ters for PL (20% w/w) DMN arrays were assessed at room temperature,
40 °C and 80 °C for 48 h, 24 h and 12 h respectively.
2.5. Fabrication of drug-loaded PL DMN
Methyleneblue (MB, 2%w/w) andﬂuorescein sodium (Flu\\Na, 20%
w/w), as a water-soluble blue (absorption wavelength of 664 nm) and
red dye (absorption wavelength of 450 nm) respectively, were mixed
into the PL (20% w/w) solutions and used as a model low molecular
weight drugs. BSA-FITC (20% w/w), as a high molecular weight model
protein with an excitation/emission wavelength of 480/520 nm, was
dissolved in the PL solutions as well. Another model biomolecule, insu-
lin (20% w/w), was dissolved in a 0.1 M HCl solution and then added to
the PL solutions. These model drugs loaded PL DMN were prepared as
per the described process in Section 2.4 and Fig. 1. The morphology of
drug-loaded DMN patches was investigated using a Keyence VHX700F
Digital Microscope (Keyence, Osaka, Japan). In addition, scanning elec-
tron microscopy (TM3030 benchtop SEM, Hitachi, Krefeld, Germany)
was used for high-resolution imaging. The instrument was operated at
15 kV and images were captured at magniﬁcations between 40 and
250×.
2.6. Mechanical and insertion properties of PL DMN
Mechanical tests were used to assess compression and insertion
properties of blank PL DMN and MB-loaded DMN arrays. These tests
were conducted using a TA-XT2 Texture Analyser in compression
mode, as reported previously [21]. Brieﬂy, to test compression, DMN ar-
rayswereﬁrst visualized using a stereomicroscope to determine the ini-
tial needle height. DMN arrays were then attached to the moveable
cylindrical probe of the Texture Analyser using double-sided adhesive
tape and pressed by the test station against a ﬂat aluminium block at a
rate of 0.5 mm/s for 30 s and a force of 0.36 N per DMN applied. Pre-
test and post-test speeds were set at 1 mm/s, and the trigger force
was set at 0.049 N. DMN heights were measured again using the
Fig. 1. Schematic representation of fabrication of PL and drug-loaded PL DMN arrays.
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plication of the axial compression load, calculated.
Insertion properties of the DMN were investigated using Paraﬁlm
M® (PF), a ﬂexible thermoplastic sheet made of oleﬁn-type material,
which has recently been highlighted as a useful skin simulant for inser-
tion of MNs [22]. The initial heights of the DMNs weremeasuredmicro-
scopically prior to the test. The PF sheet was folded into an eight-layer
ﬁlm (~1 mm thickness). Following attachment of the MN array to the
movable probe of the Texture Analyser, the probe was lowered onto
the folded PF at a speed of 1.19 mm/s until the required force of 32 N
was exerted. The force was held for 30 s. The MN arrays were then re-
moved from the polymeric sheet and the ﬁnal MN heights measured,
allowing the percentage reduction on insertion to be calculated. The
PF sheet was unfolded and the number of holes in each layer evaluated
using the stereomicroscope. The percentage of holes created versus
depth of PF was plotted [22].
2.7. Determination of water content of PL DMN
The percentage water content of PL arrays was determined with a
Q500 Thermo Gravimetric Analyser (TA Instruments, Elstree, Herts,
UK). Samples of 10.0 mg were heated from ambient temperature to
300 °C at a heating rate of 10 °C min−1. Nitrogen ﬂow rates of
40 ml min−1 (balance purge gas) and 60 ml min−1 (sample purge
gas) weremaintained for all samples. The data from thermogravimetric
analysis experiments were analyzed with TA Instruments Universal
Analysis 2000 software, version 4.4A (TA Instruments, Elstree, Herts,
UK).
2.8. Dissolution studies
The dissolution of the PL DMNs was evaluated in-situ using full-
thickness neonatal porcine skin. The skin was obtained from stillborn
piglets and excised within 24 h of birth using an electric dermatome
(Integra Life Sciences™, Padgett Instruments, NJ, USA). The skin was
then wrapped in aluminium foil and stored at−20 °C until use. Before
performing penetration studies, the skin was carefully shaved using a
disposable razor and washed with phosphate-buffered saline (PBS,
pH 7.4). Skin samples were then placed on top of dental wax, to give
the skin support and the underside of the skin bathed in PBS (pH 7.4)
at 37 °C for 30 min to equilibrate. DMN arrays were then inserted intothe centre of the skin section using manual pressure and a circular
steel weight placed on top to ensure the array remained in place.MNar-
rays were removed at various time points and immediately viewed
under a Leica EZ4 D stereomicroscope (Leica Microsystems, Milton
Keynes, UK).
2.9. Optical coherence tomography
Optical coherence tomography (OCT) was used to visualize the in-
sertion of PL DMN into full-thickness porcine skin. DMN patches were
applied with an application force of 32 N per patch by Texture Analyser
for 30 s. OCT was employedwith a laser centre wavelength of 1305.0±
15.0 nm to facilitate real-time high-resolution imaging of upper skin
layers. The skin was scanned at a frame rate of up to 15 B-scans (2D
cross-sectional scans) per second (scan width = 2.0 mm). The 2D im-
ages were examined using the imaging software ImageJ® (National In-
stitute of Health, Bethesda, USA). The scale of image ﬁles obtained was
1.0 pixel = 4.2 μm, thus allowing accurate measurements of the depth
of MN penetration, the distance between the MN baseplate and the SC
[23]. OCT images were captured immediately upon insertion and then
after 10 min post-insertion.
2.10. Insertion of MB loaded PL DMN arrays into excised neonatal porcine
skin
In this study, dermatomed neonatal porcine skin was used as a
model of the human skin because the structure of porcine skin is similar
to that of human skin [24]. Skin (approximately 350 μm thickness) was
obtained from stillborn piglets and excised within 24 h of birth using an
electric dermatome. The skin was then wrapped in aluminium foil and
stored at−20 °C until use. Before performing penetration studies, the
skin was carefully shaved using a disposable razor and washed with
phosphate-buffered saline (PBS, pH 7.4). The skin surface was dried
using tissue paper and placed dermis side down on a dental wax sheet
(Anutex®, Kemdent Works, Swindon, UK). MB (2% w/w) loaded PL
(20% w/w) DMN arrays were applied perpendicularly into the skin
using manual pressure for 30 s. Cylindrical 5.0 g stainless steel weights
were placed on top of the array to hold them in place and incubated
for 5 min, 6 h and 24 h at 37 °C. Afterwards, the DMN was removed
and the skin was visualized using the digital microscope. The number
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was recorded.2.11. Circular dichroism analysis of FITC-BSA and insulin loaded PL DMN
arrays
Samples of insulin, FITC-BSA, and biomolecules-loaded PL DMN
formulations were analyzed by circular dichroism (CD) to assess sec-
ondary structure pre- and post- formulation. FITC-BSA and insulin
loaded PL DMN were dissolved in PBS (pH 7.4) and submitted to
CD measurement (Jasco J-810, Easton, MD). CD spectra of free FITC-
BSA and insulin were also obtained by using quartz cuvettes
(0.5 ml volume, 1 mm length) on a JASCO J-810 spectrometer
equipped with a cell compartment thermo-regulated at 25 °C with
wavelength range 190 to 290 nm.2.12. Ex-vivo drug delivery from ﬂu-Na and FITC-BSA-loaded dissolving PL
DMN arrays
The permeation of Flu-Na and FITC-BSA from PL DMN arrays across
dermatomed (̴ 350 μm) neonatal porcine skin was investigated using
modiﬁed Franz diffusion cells, as described previously [25]. The drug-
loaded PL DMN array was placed on top of the dermatomed porcine
skin and inserted using manual pressure for 30 s. A 5.0 g cylindrical,
stainless steel weight was placed on top of the inserted array. The
donor compartment of the apparatus was clamped onto the receiver
compartment. The donor compartment and sampling arm were sealed
using Paraﬁlm M®. The receiver compartment contained PBS (pH 7.4)
was thermo-regulated at 37 ± 1 °C. Syringes (1.0 ml) with 8.0 cm sam-
pling needles were used to remove 200 μl of the Franz cell contents at
appropriate time points and 200 μl of pre-warmed PBS was subse-
quently added to replace this. The concentration of the released Flu-
Na and FITC-BSA in the receiver compartment was determined using
UV–vis and ﬂuorescence spectroscopy (FLUOstar®Omega, BMG labtech
ltd, Offenburg, Germany) respectively.2.13. Statistical analysis
All quantitative data were expressed as means ± SD from triplicate
measurements unless otherwise noted. Differences between groups
were assessed for signiﬁcance using an unpaired, two-tailed Student's
t-test. The threshold for signiﬁcance was p b 0.05. Statistical analysis
was performed using Prism 6 (GraphPad Software, USA).Fig. 2. (A) Viscositymeasurements of PL gel (10%, 15%, 20%, 25% and30%w/w) and (B) force req
PL gel (Means ± SD, n= 3).3. Result and discussion
3.1. Characterisation of PL gel and PL ﬁlms prepared from different
concentration
The viscosity of the aqueous PL formulations is a crucial parameter as
PL gel should be able to ﬁll the cavities ofMN siliconemouldswhen pos-
itive pressure or centrifugation forces are applied during the DMN
manufacturing. However, in order to prepare MNs with good mechani-
cal strength and also avoid shrinkage of the DMN arrays during the dry-
ing stage, it is important to use gels with sufﬁciently high polymer
concentrations. The evolution of the viscosity vs. different concentration
of PL gel is shown in Fig. 2A. Below 25%w/w concentration, PL exhibited
newtonian behaviour. These formulations presented viscosities ranging
from 0.1 to 6 Pa∙s. However, when the PL concentration reached 30%w/
w the viscosity increased signiﬁcantly (p b 0.001) and the gel formula-
tions displayed pseudoplastic behaviour. Therefore, only formulations
containing up to 25% w/w of PL is processable for DMN formulation
development.
The ﬁlm-forming polymer with good mechanical strength is re-
quired to produce the DMN. Therefore, the analysis of mechanical prop-
erties of the polymeric ﬁlm is preliminary step for the DMN
development. Fig. 2B shows that the force required to break the PL
ﬁlm is directly proportional to the initial polymer concentration. Tensile
strength of PL ﬁlms was found to be 52.4 ± 3.5 N/mm2.
3.2. Optimisation of plain PL DMN
PL DMN (20% w/w PL) was dried at higher temperatures as a way to
reduce drying time, however, the DMN baseplate surface became un-
even (Fig. 3). In comparison, DMN arrays prepared at room temperature
(25 °C), examined microscopically, displayed well-formed DMNs with
sharp tips, a complete array of needles.
The mechanical properties of DMNs should be evaluated to deter-
mine whether DMNs are strong enough to penetrate the skin and do
not breakduring skin penetration.Mechanical properties of PLMNspre-
pared using the different concentrations of PL were evaluated as de-
scribed previously by McCrudden et al. [25]. MN arrays were
compressed against a metal block. As applied force was increased,
there was a decrease in MN height but, particularly, none of the MN
fractured, rather they became slightly compressed. However, this
method does not represent the real insertion situation as skin is softer
and more ﬂexible. MN prepared using 20% w/w PL showed b21% in
height reduction when compressed using 130 N force per MN patch
(Fig. 4A). It was found to be signiﬁcant difference (P b 0.05) in height re-
duction from 10% w/w PL MN compared to rest of PL MN after PFuired to break theﬁlmwith a tensile strength that prepared fromdifferent concentration of
Fig. 3. PL (20% w/w) DMN arrays prepared and dried at different temperatures; (A) 80 °C (B) 40 °C (C) Room temperature.
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% reductions in height from 15%, 20% and 25% w/w concentration of PL
during compression and insertion tests. Considering that human typi-
cally applies 32 N when manually applying MNs, this test can be used
as quality control [22]. In order to evaluate the insertion of the arrays,
a skin simulant (Paraﬁlm M®) was used following the method de-
scribed by Larrañeta et al. [22]. After application of PL DMN array at
32 N force by Texture Analyser, the number of holes created in each
layer of the PF sheet was assessed using a light microscope. Fig. 4B
shows the percentage of holes created in each PF layer after applying
PLDMNarrays. All PL DMNarrays prepared fromdifferent PL concentra-
tion showed similar insertion proﬁles without any signiﬁcance differ-
ence (P N 0.05). Based good mechanical and insertion proﬁle of PL ﬁlm
and DMN, PL DMN prepared from 20% w/w PL gel was taken further.
The MB (2% w/w) loaded PL (20% w/w) DMN arrays showed similar
height reduction at different forces compared to blank PL (20% w/w)
DMN arrays. The insertion plot (Fig. 4) shows that the DMN arrays
could reach an insertion depth of approximately 375 μm. This means
that the application of DMN arrays with an insertion force of 0.089 N
per needle for 30 s may be suitable for penetrating the skin. Most of
the reported dissolving MN from the synthetic polymers were required
to have combination of two or more polymers or additional plasticizer
to get the enough mechanical strength [17]. While, in this work, PL
alone is sufﬁcient to get the required mechanical strength for insertion.
The water content of DMN is known to impact on mechanical prop-
erties including rigidity, ﬂexibility, and dissolution of DMN. The high
content of moisture will weaken MNs ability to penetrate the skin. TheFig. 4.Mechanical characterisation PL DMN prepared from different concentration and MB lo
compression force applied (means ± SD, n ≥ 3) and (B) Percentage of holes created in each P
(means ± SD, n = 3).water content of plain PLDMNarrayswas determined using thermogra-
vimetric analysis. Bound and free water in PL DMN were 4 ± 0.3% and
2.3 ± 0.76%, respectively. In general, the total water content of the PL
DMN arrays was b7% and this is lower than other polymeric DMNs re-
ported [14,25,26]. High levels of water content can affect the stability
of drug molecules; however, this is particularly important for biologics
that are highly sensitive to moisture. Even though these DMNs were
fabricated under normal lab conditions, manufacture of these DMNs in
a controlled temperature andhumidity could further decrease themois-
ture content of PL DMN thereby enhancing the storage stability of bio-
molecules. Nevertheless, at this water content level, we found that the
PL DMNs preserved their mechanical strength, the stability of biomole-
cules and effectively penetrated the porcine skin tissue.
Different drug molecules loaded PL DMNs that appeared to be fully
formed upon visual examination under a light microscope and were
taken for further characterisation. Irrespective of the drug molecules
and content (2% w/w MB, 20% w/w Flu Na and FITC-BSA) used in pre-
paring the DMN, they each displayed reproducible MN formation with
sharp tips. This is shown in Fig. 5 A–C with representative SEM images
of 2% w/w MB DMN displayed in Fig. 5D.
3.3. Dissolution of PL DMN after insertion into porcine skin
Dissolution studies of the PL DMN formulations were undertaken
with a view to predicting the time required for dissolution after
inserting into full-thickness porcine skin. The DMN array formulated
from PL showed dissolution of approximately 80% of needles heightaded PL MN arrays; (A) Percentage reduction in the height of the needles after different
F layer after the application of PL DMN arrays with a 0.089 N per needle insertion force
Fig. 5.Digital microscopic images of differentmolecules loaded PL DMNs: (A) 2%w/wMB loaded PLDMN (12× 12 and 19× 19), (B) 20%w/w Flu-Na loaded PL DMN (12× 12), (C) 20%w/
w FITC-BSA loaded PL DMN (12 × 12) and (E) Electron microscopic image of PL DMN.
295L.K. Vora et al. / International Journal of Biological Macromolecules 146 (2020) 290–298after 10 min. Despite the high in molecular weight of PL (~200 KDa)
compared to the reported DMNwith lowmolecular synthetic polymers
[27], complete dissolution of PL DMN arrays within 20 min as displayed
in Fig. 6Aiv. This could be useful for fast dissolving MN formulation de-
velopment compared to non-biodegradable synthetic polymers.
3.4. Optical coherence tomography
To take real-time images of the PL DMN insertion into the porcine
skin, a non-invasive optical imaging technique, OCT, was used in this
study and the images are displayed in Fig. 6B and C. The inserted part
of MN was calculated by measuring the non-inserted part of MN arrays
by analyzing the distance between the baseplate and skin surface by
ImageJ software. It was found that 403 ± 35.8 μm inserted out of totalFig. 6. (A) Representative digitalmicrographsof thedissolution of blank PLDMNarrays (prepare
a 30 min period following insertion into, and removal from excised neonatal porcine skin,
(C) Microchannel pores generated by 12 × 12 (500 μm).height of 504 ± 6.4 μm which is 80 ± 7.2% insertion. As depicted in
Fig. 6C, the visible depth of microchannel pores created by PL DMN in
full-thickness skin was 239.4 ± 8.4 μm. Moreover, the width of the cre-
ated pores was measured as 160 ± 32.6 μm, as determined from the
side view by the OCT analysis. These set of results showed that PL
DMN were mechanically strong enough to insert into the porcine skin
and further dissolve beneath the SC.
3.5. Insertion of MB loaded PL DMN arrays into excised neonatal porcine
skin
For efﬁcient intradermal delivery, it is important that MNs penetrate
into the skin and subsequently deposit their payload. The penetration
efﬁciency of DMN was quantiﬁed as a percentage of the number ofd from20%w/wPL gel) at speciﬁc timepoints (T0: 0min; T5: 5min; T10: 10min etc.) over
(B) OCT images of DMN insertion in full-thickness porcine skin 12 × 12 (500 μm) and
Fig. 7. Digital images of MB deposited holes on neonatal porcine skin after insertion of MB (2% w/w) loaded PL (20% w/w) DMN arrays at different time points: (A) 5 min, (B) 6 h and
(C) 24 h at 37 °C.
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plication of the MB loaded PL DMN array for 5 min, 6 h and 24 h. Fig. 7
shows top view of MB deposited holes in porcine skin after MB loaded
PL DMN penetration at different time points. It was found that
95–100% ofMNspenetrated into the porcine skin and this is comparable
to results achieved with solid MNs [28]. These results indicate that PL
DMN patches provide a sufﬁcient capability of penetration via SC to cre-
ate microholes, and deposit their payload after the DMN patch is peeled
off at different time points.3.6. Circular dichroism analysis of FITC-BSA and insulin loaded PL DMN
arrays
To evaluate the structural integrity of encapsulated BSA-FITC and in-
sulin in PL DMN, we used CD spectroscopy, which is widely applied to
examining the secondary conformation of proteins [29]. Insulin and
BSA are most commonly used model biomolecules in novel drug deliv-
ery [34]. We found that the CD spectra of PL DMN loaded FITC-BSA and
insulin were practically indistinguishable from that of native FITC-BSA
and insulin solution (Fig. 8), indicating that the structural integrity of
both proteins in PL DMN are preserved intact. The CD spectra of stan-
dard solutions of insulin and FITC-BSA exhibit a strong negative mini-
mum at 208 nm and a lesser pronounced minimum at 222 nm. These
bands are indicative of a typical α-helical structure. Both biomolecules
were found to be stable following 15-day storage of MN arrays under
ambient conditions. The fabrication of PL DMN does not require high
temperatures. Furthermore, the solid-state matrix of non-ionic PL poly-
mer contributes to enhanced storage stability by preventing the aggre-
gation of biomolecules at room temperature [30].Fig. 8. Stability of secondary structure of FITC-BSA and3.7. Ex-vivo release of drug-loaded PL DMN in porcine skin
This study was conceived as a proof of concept and the main objec-
tive was to explore the possibility of delivering the model biomolecules
using PL DMNs ﬁrst time. The model molecule-loaded PL arrays were
manufactured containing drug in the needle tips and in a small base-
plate. In this manner biomolecules can be delivered from the needle
tips and consequently from the baseplate. The drug conﬁned in the
baseplate can permeate through the created pores [25]. Here, to study
the permeation proﬁles of a small molecule, Flu-Na and a large protein,
BSA-FITC, PL DMN patches were inserted into porcine skin and the drug
release wasmonitored for 28 h. Fig. 9 illustrates the permeation proﬁles
of FITC-BSA and Flu-Na released from PL DMN prepared from the aque-
ous gel of 20% w/w PL. The loading of both molecules was 20% w/w in
the dry state of PL. Both molecules were detected in the receiver com-
partment of the Franz cells as soon as 15 min after application of DMN
arrays. Following application of the PL DMN for 28 h, 1479 ±
364 μg/cm2 of Flu-Na and 1105 ± 123 μg/cm2 of FITC-BSA were deliv-
ered from PL DMN arrays. As shown, BSA-FITC is a large protein with a
molecularweight of 66 kDa, and its release efﬁciency is lower compared
to Flu\\Na. It is agreed that the delivered dose fromMNs is typically re-
stricted to between themicrogram to lower milligram range. The deliv-
erable dose from DMN is deﬁned by the total array volume (i.e. shape,
size, and density of MNs) and percentage loading of the drug [26]. The
appliance of biomolecules delivery using dissolving MNs outcomes in
polymer deposition in the skin. Asmost of the drug and biomolecule de-
livery regimens require repeated application of dissolving MNs, regula-
tory bodies will need assertion of polymer safety. Accordingly, a
considerate of the long-term effects of polymer deposition will necessi-
tate further investigation to ensure they do not represent a toxicityinsulin (INS) by Circular Dichroism from PL DMN.
Fig. 9. The ex-vivo cumulative permeation proﬁle of FITC-BSA and Flu-Na across dermatomed (~350 μm)neonatal porcine skinwhen delivered using PL DMN arrays (means± S.D., n ≥ 3).
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weight synthetic polymers that not necessarily biocompatible. As
highlighted such polymer deposition may result in effects such as ery-
thema or hepatic/lymphatic accumulation and require further investi-
gation [27]. The main advantage of PL for MNmanufacture is that PL is
inherently biocompatible and this is widely discussed in the literature.
The biocompatibility of PL has signiﬁcant positive implication for repeat
application of DMN manufactured from PL, particularly in delivery of
drug/biomolecules [19,32,33]. Therefore, PL based DMN will not have
signiﬁcant long-term secondary/detrimental effects. This novel biopoly-
mer PL based DMN array could be used for the transdermal delivery of
small molecule drugs and large biomolecules up to a low milligram
dose. This preliminary formulation work using PL biopolymer supports
the growing evidence surrounding pain and needle-free, self-
administered, transdermal delivery systems. Further pre-clinical work
is required to assess the long term efﬁcacy and tolerability of PL-based
DMN for transdermal delivery.4. Conclusion
The work presented here illustrates the potential of carbohydrate
biopolymer PL-based DMN to deliver low and high molecular weight
drug molecules across the skin. These ﬁrst time fabricated DMN were
sufﬁciently robust to penetrate the skin and dissolve rapidly in the
skin to achieve effective drug permeation. PL DMN arrays were success-
fully formulated with model dyes, MB and Flu-Na as well as model pro-
tein/peptide, FITC-BSA and insulin. The stability of model compounds,
FITC-BSA and insulin, in PL DMN arrays was conﬁrmed by circular di-
chroism. PL DMN successfully managed to deliver the model com-
pounds across excised neonatal porcine skin. Therefore, these self-
dissolving microneedles fabricated from biopolymer PL with good me-
chanical strength and biocompatibility make a viable alternative for en-
hanced transdermal drug delivery. PL DMN can be developed as a pain-
free alternative to traditional needle-based administration for small and
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